5:13 PM ET
8-K
Capital Raise
Clene Capital Raise of $4M
Clene Inc. entered into a securities purchase agreement for a $4.0 million registered direct offering of 1,219,513 shares of common stock at $3.28 per share. The offering was led by the company's Chairman and CEO alongside existing investors to fund regulatory filings for its lead drug candidate, CNM-Au8, and general corporate purposes. The proceeds are expected to extend the company's cash runway through mid-first quarter 2027.
- Value
- $4M
- Counterparty
- David Matlin, Kensington Capital Holdings, and other existing stockholders